miR-200 Regulates PDGF-D-Mediated Epithelial–Mesenchymal Transition, Adhesion, and Invasion of Prostate Cancer Cells

Authors

  • Dejuan Kong,

    1. Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA
    Search for more papers by this author
  • Yiwei Li,

    1. Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA
    Search for more papers by this author
  • Zhiwei Wang,

    1. Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA
    Search for more papers by this author
  • Sanjeev Banerjee,

    1. Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA
    Search for more papers by this author
  • Aamir Ahmad,

    1. Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA
    Search for more papers by this author
  • Hyeong-Reh Choi Kim,

    1. Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA
    Search for more papers by this author
  • Fazlul H. Sarkar

    Corresponding author
    1. Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA
    • Department of Pathology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, 740 Hudson Webber Cancer Research Center, 4100 John R, Detroit, Michigan 48201, USA
    Search for more papers by this author
    • Telephone: 313-576-8327; Fax: 313-576-8389


  • Author contributions: D.K.: conception and design, execution, collection of data and data analysis, manuscript writing; Y.L.: experimental design, data analysis, manuscript writing; Z.W.: experimental design and execution, data analysis; S.B.: experimental design, execution, and data analysis; A.A.: experimental execution and collection of data; H.-R.C.K.: development of LNCaP PDGF-D and PC3 PDGF-D cell lines and experimental design; F.H.S.: principal investigator, conception and design, laboratory facility and financial support, experimental design, data collection and interpretation, manuscript writing, final approval of the manuscript.

  • First published online in STEM CELLS EXPRESS April 23, 2009.

Abstract

MicroRNAs have been implicated in tumor progression. Recent studies have shown that the miR-200 family regulates epithelial–mesenchymal transition (EMT) by targeting zinc-finger E-box binding homeobox 1 (ZEB1) and ZEB2. Emerging evidence from our laboratory and others suggests that the processes of EMT can be triggered by various growth factors, such as transforming growth factor β and platelet-derived growth factor-D (PDGF-D). Moreover, we recently reported that overexpression of PDGF-D in prostate cancer cells (PC3 PDGF-D cells) leads to the acquisition of the EMT phenotype, and this model offers an opportunity for investigating the molecular interplay between PDGF-D signaling and EMT. Here, we report, for the first time, significant downregulation of the miR-200 family in PC3 PDGF-D cells as well as in PC3 cells exposed to purified active PDGF-D protein, resulting in the upregulation of ZEB1, ZEB2, and Snail2 expression. Interestingly, re-expression of miR-200b in PC3 PDGF-D cells led to reversal of the EMT phenotype, which was associated with the downregulation of ZEB1, ZEB2, and Snail2 expression, and these results were consistent with greater expression levels of epithelial markers. Moreover, transfection of PC3 PDGF-D cells with miR-200b inhibited cell migration and invasion, with concomitant repression of cell adhesion to the culture surface and cell detachment. From these results, we conclude that PDGF-D-induced acquisition of the EMT phenotype in PC3 cells is, in part, a result of repression of miR-200 and that any novel strategy by which miR-200 could be upregulated would become a promising approach for the treatment of invasive prostate cancer. STEM CELLS 2009;27:1712–1721

Ancillary